Demonstration of safety in Alzheimer's patients for intervention with an anti-hypertensive drug Nilvadipine: Results from a 6-week open label study

International Journal of Geriatric Psychiatry

Volumn 26, Issue 10, 2011, Pages 1038-1045

  Kennelly, S P ^a,b   Abdullah, L ^c   Paris, D ^c   Parish, J ^c   Mathura, V ^c   Mullan, M ^c   Crawford, F ^c   Lawlor, B A ^a,b   Kenny, R A ^c  

^a ST JAMES S HOSPITAL   (Ireland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

^c ROSKAMP INSTITUTE   (United States)

Author keywords

Alzheimer's; anti hypertensive; calcium; Nilvadipine; tolerability

Indexed keywords

NILVADIPINE;

ADULT; AGED; ALZHEIMER DISEASE; ANALYTICAL EQUIPMENT; ANTIHYPERTENSIVE THERAPY; ARTHRALGIA; ARTICLE; BACKACHE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BRADYCARDIA; COLLAPSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FINOMETER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEADACHE; HOT FLUSH; HUMAN; HYPERTENSION; HYPOTENSION; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; PRESYNCOPE; RESPIRATORY TRACT INFECTION; SEX DIFFERENCE; SIDE EFFECT; SPHYGMOMANOMETER; SYMPTOMATIC BRADYCARDIA; SYNCOPE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; URINARY TRACT INFECTION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; FEMALE; HUMANS; MALE; MIDDLE AGED; NIFEDIPINE;

EID: 80052706430     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.2638     Document Type: Article

References (36)

1. Allan LM, Ballard CG, Allen J, et al,. 2007. Autonomic dysfunction in dementia. J Neurol Neurosurg Psychiatry 78: 671-6717.
2. Andersson M, Hansson O, Minthon L, Ballard CG, Londos E,. 2008. The period of hypotension following orthostatic challenge is prolonged in dementia with Lewy bodies. Int J Geriatr Psychiatry 23: 192-198. (Pubitemid 351308500)
3. Applegate WB, Davis BR, Black HR, et al,. 1991. Prevalence of postural hypotension at baseline in the systolic hypertension in the elderly program (SHEP) cohort. J Am Geriatr Soc 39: 1057-1064.
4. Chobanian AV, Bakris GL, Black HR, et al,. 2003. The Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289: 2560-2572. (Pubitemid 37430158)
5. Craig GM,. 1994. Clinical presentation of orthostatic hypotension in the elderly. Postgrad Med J 70: 638-642. (Pubitemid 24276890)
6. Cribbs DH, Agadjanyan MG,. 2009. Active and passive Abeta-immunotherapy: preclinical and clinical studies and future directions: part II. CNS Neurol Disord Drug Targets 8: 82-87.
7. Drayer JI, Weber MA, Gardin JM, Lipson JL,. 1983. Effect of long-term antihypertensive therapy on cardiac anatomy in patients with essential hypertension. Am J Med 75: 116-120. (Pubitemid 13009944)
8. Dupont AG, Coupez JM, Jensen P, et al,. 1991. Twenty-four hour ambulatory blood pressure profile of a new slow-release formulation of diltiazem in mild to moderate hypertension. Cardiovasc Drugs Ther 5: 701-707.
9. Farlow MR, Miller ML, Pejovic V,. 2008. Treatment options in Alzheimer's disease: maximizing benefit, managing expectations. Dement Geriatr Cogn Disord 25: 408-422. (Pubitemid 351630074)
10. Faust G,. 1992. The tolerability of nilvadipine compared to nifedipine in patients with essential hypertension. J Cardiovasc Pharmacol 20 (Suppl 6): S56-S61. (Pubitemid 23002800)
11. Ferri CP, Prince M, Brayne C, et al,. 2005. Global prevalence of dementia: a Delphi consensus study. Lancet 366: 2112-2117. (Pubitemid 41797645)
12. Forette F, Seux ML, Staessen JA, et al,. 1998. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 352: 1347-1351. (Pubitemid 28510916)
13. Forette F, Seux ML, Staessen JA, et al,. 2002. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 162: 2046-2052. (Pubitemid 35168212)
14. Fotherby MD, Robinson TG, Potter JF,. 1994. Clinic and 24h blood pressure in elderly treated hypertensives with postural hypotension. J Hum Hypertens 8: 711-716. (Pubitemid 24276970)
15. Hanyu H, Hirao K, Shimizu S, et al,. 2007. Nilvadipine prevents cognitive decline of patients with mild cognitive impairment. Int J Geriatr Psychiatry 22: 1264-1266. (Pubitemid 350285434)
16. Kawahara M, Negishi-Kato M, Sadakane Y,. 2009. Calcium dyshomeostasis and neurotoxicity of Alzheimer's beta-amyloid protein. Expert Rev Neurother 9: 681-693.
17. Keck M,. 1992. Comparison of the efficacy of nilvadipine and nitrendipine on circadian blood pressure. J Cardiovasc Pharmacol 20 (Suppl 6): S43-S49. (Pubitemid 23002798)
18. Leonetti G,. 2005. Effects of nilvadipine and amlodipine in patients with mild to moderate essential hypertension: a double blind, prospective, randomised clinical trial. Curr Med Res Opin 21: 951-958. (Pubitemid 40896243)
19. Lopez-Arrieta JM, Birks J,. 2002. Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev C D000147.
20. Mathias CJ, Mallipeddi R, Bleasdale-Barr K,. 1999. Symptoms associated with orthostatic hypotension in pure autonomic failure and multiple system atrophy. J Neurol 246: 893-898. (Pubitemid 29512158)
21. Maxwell CJ, Hogan DB, Ebly EM,. 1999. Calcium-channel blockers and cognitive function in elderly people: results from the canadian study of health and aging. CMAJ 161: 501-506. (Pubitemid 29433523)
22. McKhann G, Drachman D, Folstein M, et al,. 1984. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 34: 939-944. (Pubitemid 14076461)
23. Mounier-Vehier C, Bernaud C, Carre A, et al,. 1998. Compliance and antihypertensive efficacy of amlodipine compared with nifedipine slow-release. Am J Hypertens 11: 478-486. (Pubitemid 28231461)
24. O'Brien E, Coats A, Owens P, et al,. 2000. Use and interpretation of ambulatory blood pressure monitoring: recommendations of the British hypertension society. BMJ 320: 1128-1134. (Pubitemid 30213975)
25. Palatini P, Frigo G, Bertolo O, et al,. 1998. Validation of the A&D TM-2430 device for ambulatory blood pressure monitoring and evaluation of performance according to subjects' characteristics. Blood Press Monit 3: 255-260. (Pubitemid 28521776)
26. Pickering T,. 1996. Recommendations for the use of home (self) and ambulatory blood pressure monitoring. American society of hypertension ad hoc panel. Am J Hypertens 9: 1-11. (Pubitemid 26060844)
27. Rigaud AS, Fagnani F, Bayle C, et al,. 2003. Patients with Alzheimer's disease living at home in France: costs and consequences of the disease. J Geriatr Psychiatry Neurol 16: 140-145. (Pubitemid 37409022)
28. Schuff N, Matsumoto S, Kmiecik J, et al,. 2009. Cerebral blood flow in ischemic vascular dementia and Alzheimer's disease, measured by arterial spin-labeling magnetic resonance imaging. Alzheimers Dement 5: 454-462.
29. Strandgaard S,. 1993. The cerebral circulation in the elderly: the influence of age, vascular disease, and antihypertensive treatment. Am J Geriatr Cardiol 2: 32-36. (Pubitemid 24003508)
30. Takakura S, Sogabe K, Satoh H, et al,. 1992. Nilvadipine as a neuroprotective calcium entry blocker in a rat model of global cerebral ischemia. A comparative study with nicardipine hydrochloride. Neurosci Lett 141: 199-202.
31. Trompet S, Westendorp RG, Kamper AM, De Craen AJ,. 2006. Use of calcium antagonists and cognitive decline in old age the Leiden 85-plus study. Neurobiol Aging. 29 (2): 306-308.
32. Uchida S, Yamada S, Nagai K, Deguchi Y, Kimura R,. 1997. Brain pharmacokinetics and in vivo receptor binding of 1,4-dihydropyridine calcium channel antagonists. Life Sci 61: 2083-2090. (Pubitemid 27478835)
33. van der Velde N, Van Den Meiracker AH, Stricker BH, Van Der Cammen TJ,. 2007. Measuring orthostatic hypotension with the Finometer device: is a blood pressure drop of one heartbeat clinically relevant? Blood Press Monit 12: 167-171. (Pubitemid 46743720)
34. Weir MR, Vlachkis ND, Dequattro V, et al,. 1990. Evaluation of the clinical pharmacology of nilvadipine in patients with mild to moderate essential hypertension. J Clin Pharmacol 30: 425-437. (Pubitemid 20228345)
35. The consensus committee of the American Autonomic Society and the American Academy of Neurology. 1996. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy Neurology 46: 1470.
36. Yasar S, Corrada M, Brookmeyer R, Kawas C,. 2005. Calcium channel blockers and risk of AD: the baltimore longitudinal study of aging. Neurobiol Aging 26: 157-163. (Pubitemid 39600576)